Redeye initiates coverage of BICO, a leading player in the bioconvergence space. After a turbulent period, the company has taken steps to restore focus on return to growth and strengthen its balance sheet. This creates a turnaround opportunity that, if executed successfully, could justify significant multiple expansion from the current valuation of just around 1x current-year sales.
LÄS MER
